Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Dermatologic 1CNS 1Breast 1

Conditions

Brain Neoplasms 4Breast Neoplasms 3Recurrence 2Glioblastoma 2Triple Negative Breast Neoplasms 1Oligodendroglioma 1Melanoma 1Lung Neoplasms 1Glioma 1Carcinoma, Hepatocellular 1Astrocytoma 1

Interventions

Sorafenib 121Nivolumab 36pembrolizumab 32Bevacizumab 28lenvatinib 27Doxorubicin 23Radiosurgery 21Radiofrequency Ablation 20Oxaliplatin 20Hepatectomy 18Fluorouracil 15Capecitabine 15Magnetic Resonance Spectroscopy 14atezolizumab 13Leucovorin 13Cisplatin 13Gemcitabine 11Erlotinib Hydrochloride 11tislelizumab 9Sirolimus 9Radiotherapy 9Irinotecan 9Ipilimumab 9cabozantinib 8Liver Transplantation 8regorafenib 7Ramucirumab 7Folfox protocol 7Embolization, Therapeutic 7sintilimab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Carcinoma, Hepatocellular × paclitaxel-Angiopep-2 conjugate × Clear all
NCT00539383 2014-07-31

A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Advanced Solid Tumors and Metastatic Brain Cancer

Angiochem Inc

Phase 1 Completed
56 enrolled
BreastCNSDermatologicGastrointestinalThoracic

Brain Neoplasms, Breast Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡